William E. Gillanders

TL;DR: Tumour-specific mutant proteins are identified as a major class of T-cell rejection antigens following anti-PD-1 and/or anti-CTLA-4 therapy of mice bearing progressively growing sarcomas, and it is shown that therapeutic synthetic long-peptide vaccines incorporating these mutant epitopes induce tumour rejection comparably to checkpoint blockade immunotherapy.

TL;DR: Deep sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not observed in standard cell lines.

TL;DR: This is the first study to demonstrate that PD-L1 expression is an independent negative prognostic factor in human breast cancer, which has important implications for the application of antibody therapies targeting the PD-1/PD- L1 signaling pathway in this disease.

TL;DR: It is shown, in both human pancreatic adenocarcinoma and a murine pancreatic tumor model (Pan02), that tumor cells produce increased levels of ligands for the CCR5 chemokine receptor and, reciprocally, that CD4+ Foxp3+ Tregs, compared with CD4-Foxp3− effector T cells, preferentially express C CR5.

TL;DR: This is the first study to demonstrate that the presence ofPD-1+ TIL is associated with poor prognosis in human breast cancer, with important implications for the potential application of antibody therapies targeting the PD-1/PD-L1 signaling pathway in this disease.